Literature DB >> 2688634

Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism.

P M Shaw1, T S Barnes, D Cameron, J Engeset, W T Melvin, G Omar, J C Petrie, W R Rush, C P Snyder, P H Whiting.   

Abstract

A form of human hepatic microsomal cytochrome P-450 (P450hA7) with subunit Mr 50,400 has been purified from an epileptic who had been receiving long-term treatment with anticonvulsant drugs. P450hA7 metabolized the immunosuppressant drug cyclosporin A and the dihydropyridine calcium channel antagonist nifedipine, but did not metabolize a similar dihydropyridine drug, nicardipine, nor a series of alkoxyresorufin model substrates. The hepatic microsomal concentration of P450hA7 was higher in five individuals who had been receiving long-term anticonvulsant treatment than in any of 21 individuals who had not been similarly treated. The mean P450hA7 concentration in the treated individuals was 5-fold higher than the mean concentration in the untreated individuals. It is concluded that P450hA7 is a member of the cytochrome P450III family which is induced by anticonvulsant drugs in man.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2688634      PMCID: PMC1133483          DOI: 10.1042/bj2630653

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

Review 2.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

Review 3.  Cytochrome P-450: a pharmacological necessity or a biochemical curiosity?

Authors:  M D Burke
Journal:  Biochem Pharmacol       Date:  1981-02-01       Impact factor: 5.858

4.  Biochemical characterization of hepatic microsomal leukotriene B4 hydroxylases.

Authors:  M C Romano; R D Eckardt; P E Bender; T B Leonard; K M Straub; J F Newton
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

5.  The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid.

Authors:  T C Orton; G L Parker
Journal:  Drug Metab Dispos       Date:  1982 Mar-Apr       Impact factor: 3.922

6.  Inactivation of key metabolic enzymes by mixed-function oxidation reactions: possible implication in protein turnover and ageing.

Authors:  L Fucci; C N Oliver; M J Coon; E R Stadtman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

7.  Are the decreases in hepatic cytochrome P-450 and other drug-metabolising enzymes caused by indomethacin in vivo mediated by intestinal bacterial endotoxins? 16,16-Dimethylprostaglandin F2 alpha prevents decreases in hepatic drug-metabolising enzymes due to exogenous endotoxin.

Authors:  M Falzon; A S Milton; M D Burke
Journal:  Biochem Pharmacol       Date:  1984-04-15       Impact factor: 5.858

8.  Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography.

Authors:  Y Yasukochi; B S Masters
Journal:  J Biol Chem       Date:  1976-09-10       Impact factor: 5.157

9.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes.

Authors:  P P Wang; P Beaune; L S Kaminsky; G A Dannan; F F Kadlubar; D Larrey; F P Guengerich
Journal:  Biochemistry       Date:  1983-11-08       Impact factor: 3.162

10.  Decreased hepatic microsomal cytochrome P450 due to indomethacin: protective roles of 16,16-dimethylprostaglandin F2 alpha and inducing agents.

Authors:  M D Burke; M Falzon; A S Milton
Journal:  Biochem Pharmacol       Date:  1983-02-01       Impact factor: 5.858

View more
  8 in total

Review 1.  Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.

Authors:  P Glue; C R Banfield; J L Perhach; G G Mather; J K Racha; R H Levy
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.

Authors:  L M Forrester; C J Henderson; M J Glancey; D J Back; B K Park; S E Ball; N R Kitteringham; A W McLaren; J S Miles; P Skett
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

3.  Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions.

Authors:  H Bohets; K Lavrijsen; J Hendrickx; J van Houdt; V van Genechten; P Verboven; W Meuldermans; J Heykants
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

5.  Xenobiotic metabolising enzyme expression in colonic neoplasia.

Authors:  J A McKay; G I Murray; R J Weaver; S W Ewen; W T Melvin; M D Burke
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

6.  Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause-effect relationship with metabolism inhibition.

Authors:  F Serino; J Grevel; K L Napoli; B D Kahan; H W Strobel
Journal:  Mol Cell Biochem       Date:  1993-05-26       Impact factor: 3.396

7.  Factors affecting the absolute bioavailability of nifedipine.

Authors:  T J Rashid; U Martin; H Clarke; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

8.  Cytochrome P450 CYP3A in human renal cell cancer.

Authors:  G I Murray; M C McFadyen; R T Mitchell; Y L Cheung; A C Kerr; W T Melvin
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.